

Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics

Cellanyx Diagnostics News – Announcement of New Board Member Mr. Amar Kendale

January 8, 2013

Cellanyx is pleased to announce the appointment of Mr. Amar Kendale to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Mr. Kendale comes with tremendous business and leadership talent. Currently, Mr. Kendale is involved with mc10 as Vice President of Marketing. Mr. Kendale has over a decade of experience in the life sciences industry, with executive leadership roles spanning marketing, corporate development, and product development. Previously, he was Vice President of Marketing at Arsenal Medical, where he initiated the company's bio-absorbable stent development program (clinical-stage) to treat peripheral artery disease. Mr. Kendale completed his Bachelors and Masters degrees from MIT in mechanical engineering.

Mr. Kendale is excited to engage and apply his expertise to the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that he will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

###

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.
One Marina Park Drive,
14th floor
Boston, MA, 02210
Main: 571.212.9991
Email: info@cellanyx.com